Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Recurrent Grade II/III Glioma
NCT01164189Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2011
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of bevacizumab in glioma, sponsored by European Organisation for Research and Treatment of Cancer. Started Feb 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioma
Beyond the preview
Go deeper on NCT01164189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01164189.